Anyone communicating with the patient should clearly understand that responsibility should not be acknowledged when discussing an adverse event. However, it can be difficult for providers and patients to distinguish between statements that convey empathy, support, and interest in the patient`s well-being and statements that express regret about why something happened. Clear and thoughtful words should be used to convey these often sensitive messages. For example, compare “We all hope for a better outcome here and I will do what I can to accompany the patient on the path to a full recovery” with “This result should not have happened. It was a mistake because of my mistake. It is advisable to contact your professional liability insurance and possibly a lawyer before talking to a patient or family about an adverse event. Where compensation to a patient after an adverse event is an appropriate consideration, such an offer should only be made after such consultation. (b) No later than July 1, 2007, the Mayor shall establish, within the Department of Health and Human Services, a centralized system for recording and analyzing adverse events in the District of Columbia. Perhaps the main benefit of an open dialogue with patients and their families about an adverse event is the promotion of trust. While conversations about an adverse event can be difficult, patients may feel excluded or discouraged by a lack of communication. A frustrated patient might believe that the only way to get the information they are looking for is through the discovery process in a legal dispute.
In some cases, discussions after the event will satisfy a patient`s desire for information. Even in cases where a patient takes legal action after disclosing an adverse event, these conversations allow providers to disclose their terms before a lawsuit is filed and as long as the memories are still relatively fresh, the same information that is likely to be discovered in a subsequent legal battle. In addition, a patient or family member who is inclined to do so because of an adverse event is likely to do so, regardless of whether or not information about the adverse event is disclosed. A doctor who is confronted with facts at the time of an adverse event may be judged more favorably by a jury, as opposed to a doctor who is supposed to have information that he hides from a patient. If an external party manages a registration, ISGs must be submitted to sponsors as soon as possible after the registration has become aware of the event. In this situation, the registration is an agent of the sponsor, and the FDA`s requirement to declare 15 calendars begins as soon as the registration becomes aware of the event. (See section 7 below.) This transmission can be done by telephone or fax or by means of automated rules integrated into the vehicle used for data collection (e.g. automatic triggers that can be integrated into electronic data acquisition programs). For applications for direct marketing authorisation, form MedWatch 3500A16 should be used for the post-authorisation declaration of medicinal products and therapeutic biologics, unless other methods of submission are agreed. For vaccines, the Vaccine Adverse Event Reporting System should be consulted.17 Foreign events can be submitted on a CIOMS form (the Council of the World Health Organization for International Organizations of Medical Sciences),8, 18, 19 or a letter containing the relevant information in narrative form. Once the suspicion has been raised that an unexpected serious event has a reasonable way to be causally related to a drug, the EA must be reported via MedWatch to the FDA, the company that manufactures the product, or the Registration Coordination Center. (See Chapter 11.) A system should be developed so that all corresponding events are recorded and duplicate messages are avoided as far as possible.
In general, EI reports are delivered directly from the website or registration to the manufacturer, as they are often the most effective in assessing, processing and producing reports for regulatory purposes within the required time frames. Alternatively, sites may be asked to report side effects directly to the FDA in accordance with their normal practices for marketed products; However, this often means that companies are not informed about EI and are not able to track or evaluate the event as part of their security database. In fact, companies are not necessarily notified by the FDA when an EA report is sent directly to the FDA, as only certain reports are shared with industry and registrants have the option to request that the information not be shared directly with the company.14 When websites report AEs directly to the FDA, this process can also lead to accidental duplication of information for events, which are recorded by both the registry and the company. Vaccine manufacturers are required to report to VAERS any adverse events of which they become aware. (v) Submission of IND Safety Reports. The sponsor must submit each IND safety report in a narrative format or on the FDA Form 3500A or in an electronic format that the FDA can process, review, and archive. The FDA will regularly publish guidelines on the provision of electronic submissions (e.g., transfer method, media, file formats, preparation, and file organization). The sponsor may file suspected adverse reactions abroad on a Form I from the Council of International Organizations of Medical Sciences (CIOMS) instead of an FDA Form 3500A. Reports on aggregate results or pooled analyses from published and unpublished in vitro, animal, epidemiological or clinical studies should be submitted in narrative form. Any notice to the FDA must include a prominent identification of its contents, i.e., an “IND safety report,” and must be submitted to the review department of the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research, which is responsible for the IND review.
At the request of the FDA, the sponsor must provide the FDA with any additional data or information that the Agency deems necessary as soon as possible, but no later than 15 calendar days after receipt of the request. In addition to these legal requirements, registries must establish clear reporting procedures for privacy violations or other risks that are known throughout the registry, whether or not they are subject to HIPAA or state laws.